retatrutide phase 2 nejm 2023 obesity trial jastreboff 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide, a TRIPLE agonist (GLP1,

Gasoyan added that, in this large observational study of patients who discontinued semaglutide or tirzepatide, reinitiation of the original medication or receipt of alternative obesity treatment was common, which may explain why they regained less weight than patients in randomized trials. Additionally, previous research suggests that GLP-1 drug discontinuation often occurs for practical reasons rather than lack of effectiveness

I am unable to contact anyone at the company and have reported them to BBB

Evidence from trials describes groups, not personal outcomes

Tackling emotional triggers, stress, and mood can enhance long-term results

They can also help provide dietary guidelines and more

You can take injectable semaglutide at any time of the day without regard to meals